{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:50:17Z","timestamp":1789627817544,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05265-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:24:41Z","timestamp":1760444681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hypofractionated vs. conventional fractionated radiotherapy in the temozolomide era for elderly patients with glioblastoma: a systematic review and meta-analysis by the Korean Society for Neuro-Oncology"],"prefix":"10.1007","volume":"176","author":[{"given":"Eunji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hoon","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Zoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hoon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihwan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Woo","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"5265_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2015\u20132019. Neuro Oncol 24:v1\u2013v95. https:\/\/doi.org\/10.1093\/neuonc\/noac202","journal-title":"Neuro Oncol"},{"key":"5265_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5265_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000522611","volume":"56","author":"G Alexopoulos","year":"2022","unstructured":"Alexopoulos G, Zhang J, Karampelas I, Patel M, Kemp J, Coppens J, Mattei TA, Mercier P (2022) Long-Term time series forecasting and updates on survival analysis of glioblastoma multiforme: A 1975\u20132018 Population-Based study. Neuroepidemiology 56:75\u201389. https:\/\/doi.org\/10.1159\/000522611","journal-title":"Neuroepidemiology"},{"key":"5265_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2017.02.014","volume":"123","author":"CW Wee","year":"2017","unstructured":"Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH (2017) Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol 123:106\u2013111. https:\/\/doi.org\/10.1016\/j.radonc.2017.02.014","journal-title":"Radiother Oncol"},{"key":"5265_CR5","unstructured":"Central Nervous System Cancers (2024) (version 3. 2024). National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf"},{"key":"5265_CR6","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.3390\/cancers15235650","volume":"15","author":"C Jiang","year":"2023","unstructured":"Jiang C, Mogilevsky C, Belal Z, Kurtz G, Alonso-Basanta M (2023) Hypofractionation in glioblastoma: an overview of Palliative, Definitive, and exploratory uses. Cancers 15:5650","journal-title":"Cancers"},{"key":"5265_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/s1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol 13:916\u2013926. https:\/\/doi.org\/10.1016\/s1470-2045(12)70265-6","journal-title":"Lancet Oncol"},{"key":"5265_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/jco.2004.06.082","volume":"22","author":"W Roa","year":"2004","unstructured":"Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583\u20131588. https:\/\/doi.org\/10.1200\/jco.2004.06.082","journal-title":"J Clin Oncol"},{"key":"5265_CR9","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1200\/jco.2007.25.18_suppl.2042","volume":"25","author":"HM El-Shenshawy","year":"2007","unstructured":"El-Shenshawy HM, El-Razek AA, Bader H (2007) Hypofractionated radiotherapy versus conventional fractionated radiotherapy in elderly patients with glioblastoma multiforme. J Clin Oncol 25:2042\u20132042. https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.2042","journal-title":"J Clin Oncol"},{"key":"5265_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13014-020-01584-6","volume":"15","author":"JC Trone","year":"2020","unstructured":"Trone JC, Vallard A, Sotton S, Ben Mrad M, Jmour O, Magn\u00e9 N, Pommier B, Laporte S, Ollier E (2020) Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis. Radiat Oncol 15:145. https:\/\/doi.org\/10.1186\/s13014-020-01584-6","journal-title":"Radiat Oncol"},{"key":"5265_CR11","doi-asserted-by":"publisher","first-page":"e0257384","DOI":"10.1371\/journal.pone.0257384","volume":"16","author":"SM Melo","year":"2021","unstructured":"Melo SM, Marta GN, Latorraca COC, Martins CB, Efthimiou O, Riera R (2021) Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis. PLoS ONE 16:e0257384. https:\/\/doi.org\/10.1371\/journal.pone.0257384","journal-title":"PLoS ONE"},{"key":"5265_CR12","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.21873\/anticanres.16484","volume":"43","author":"O Zemskova","year":"2023","unstructured":"Zemskova O, Pedachenko E, Yu NY, Rades D (2023) Hypo-fractionated radiotherapy (HF-RT) versus conventionally fractionated radiotherapy (CF-RT) for glioblastoma. Anticancer Res 43:3121\u20133128. https:\/\/doi.org\/10.21873\/anticanres.16484","journal-title":"Anticancer Res"},{"key":"5265_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijrobp.2014.09.013","volume":"91","author":"G Minniti","year":"2015","unstructured":"Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM (2015) Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant Temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys 91:109\u2013115. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.09.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5265_CR14","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1078-0432.Ccr-19-3359","volume":"26","author":"F Nassiri","year":"2020","unstructured":"Nassiri F, Taslimi S, Wang JZ, Badhiwala JH, Dalcourt T, Ijad N, Pirouzmand N, Almenawer S, Stupp R, Zadeh G (2020) Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: A systematic review and network Meta-analysis. Clin Cancer Res 26:2664\u20132672. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3359","journal-title":"Clin Cancer Res"},{"key":"5265_CR15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5265_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4082\/kjfm.23.0034","volume":"44","author":"HJ Seo","year":"2023","unstructured":"Seo HJ, Kim SY, Lee YJ, Park JE (2023) RoBANS 2: A revised risk of bias assessment tool for nonrandomized studies of interventions. Korean J Fam Med 44:249\u2013260. https:\/\/doi.org\/10.4082\/kjfm.23.0034","journal-title":"Korean J Fam Med"},{"key":"5265_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijrobp.2015.01.017","volume":"92","author":"ND Arvold","year":"2015","unstructured":"Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM (2015) Hypofractionated versus standard radiation therapy with or without Temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 92:384\u2013389. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5265_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-020-03468-x","volume":"148","author":"CW Wee","year":"2020","unstructured":"Wee CW, Kim IH, Park CK, Kim N, Suh CO, Chang JH, Lim DH, Nam DH, Kim IA, Kim CY, Oh YT, Chung WK, Kim SH (2020) Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection? J Neurooncol 148:57\u201365. https:\/\/doi.org\/10.1007\/s11060-020-03468-x","journal-title":"J Neurooncol"},{"key":"5265_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-015-1923-x","volume":"125","author":"G Lombardi","year":"2015","unstructured":"Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall\u2019Agata M, Eoli M, Della Puppa A, Pambuku A, D\u2019Avella D, Berti F, Ruda R, Zagonel V (2015) Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant Temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian association of Neuro-Oncology). J Neurooncol 125:359\u2013367. https:\/\/doi.org\/10.1007\/s11060-015-1923-x","journal-title":"J Neurooncol"},{"key":"5265_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.prro.2015.12.001","volume":"6","author":"TJC Wang","year":"2016","unstructured":"Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd (2016) Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent Temozolomide in elderly patients with newly diagnosed glioblastoma. Pract Radiat Oncol 6:306\u2013314. https:\/\/doi.org\/10.1016\/j.prro.2015.12.001","journal-title":"Pract Radiat Oncol"},{"key":"5265_CR21","doi-asserted-by":"publisher","first-page":"Cns47","DOI":"10.2217\/cns-2019-0017","volume":"8","author":"MY Chong","year":"2019","unstructured":"Chong MY, Lorimer CF, Mehta S, Ibrahim E, Brock J, McBain C, McLoone P, Chalmers AJ (2019) An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment? CNS Oncol 8:Cns47. https:\/\/doi.org\/10.2217\/cns-2019-0017","journal-title":"CNS Oncol"},{"key":"5265_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13014-017-0929-2","volume":"12","author":"J Biau","year":"2017","unstructured":"Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Muller-Barthelemy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P (2017) Radiotherapy plus Temozolomide in elderly patients with glioblastoma: a real-life report. Radiat Oncol 12:197. https:\/\/doi.org\/10.1186\/s13014-017-0929-2","journal-title":"Radiat Oncol"},{"key":"5265_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-019-03155-6","volume":"143","author":"VM Lu","year":"2019","unstructured":"Lu VM, Kerezoudis P, Brown DA, Burns TC, Quinones-Hinojosa A, Chaichana KL (2019) Hypofractionated versus standard radiation therapy in combination with Temozolomide for glioblastoma in the elderly: a meta-analysis. J Neurooncol 143:177\u2013185. https:\/\/doi.org\/10.1007\/s11060-019-03155-6","journal-title":"J Neurooncol"},{"key":"5265_CR24","doi-asserted-by":"publisher","first-page":"Cd013261","DOI":"10.1002\/14651858.CD013261.pub2","volume":"3","author":"C Hanna","year":"2020","unstructured":"Hanna C, Lawrie TA, Rogozi\u0144ska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R (2020) Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev 3:Cd013261. https:\/\/doi.org\/10.1002\/14651858.CD013261.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5265_CR25","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.680","author":"HI Lee","year":"2024","unstructured":"Lee HI, Kim J, Kim IA, Lee JH, Cho J, Rahman R, Fell G, Wee CW, Yoon HI (2024) Choosing wisely between radiotherapy Dose-Fractionation schedules: the molecular graded prognostic assessment for elderly glioblastoma patients. Cancer Res Treat. https:\/\/doi.org\/10.4143\/crt.2024.680","journal-title":"Cancer Res Treat"},{"key":"5265_CR26","doi-asserted-by":"publisher","first-page":"e22721","DOI":"10.1097\/md.0000000000022721","volume":"99","author":"J Park","year":"2020","unstructured":"Park J, Yea JW, Park JW (2020) Hypofractionated radiotherapy versus conventional radiotherapy for diffuse intrinsic Pontine glioma: A systematic review and meta-analysis. Med (Baltim) 99:e22721. https:\/\/doi.org\/10.1097\/md.0000000000022721","journal-title":"Med (Baltim)"},{"key":"5265_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3349\/ymj.2022.0352","volume":"64","author":"N Kim","year":"2023","unstructured":"Kim N, Lim DH, Choi JW, Lee J-I, Kong D-S, Seol HJ, Nam D-H (2023) Clinical outcomes of moderately hypofractionated concurrent chemoradiotherapy for newly diagnosed glioblastoma. Yonsei Med J 64:94\u2013103","journal-title":"Yonsei Med J"},{"key":"5265_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/cco-22-76","volume":"11","author":"JK Matsui","year":"2022","unstructured":"Matsui JK, Perlow HK, Facer BD, McCalla A, Marrazzo L, Detti B, Scorsetti M, Clerici E, Scoccianti S, Navarria P, Trifiletti DM, Gondi V, Bovi J, Huang J, Brown PD, Palmer JD (2022) Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques. Chin Clin Oncol 11:38","journal-title":"Chin Clin Oncol"},{"key":"5265_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","volume":"5","author":"MD Walker","year":"1979","unstructured":"Walker MD, Strike TA, Sheline GE (1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725\u20131731. https:\/\/doi.org\/10.1016\/0360-3016(79)90553-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5265_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00066-014-0638-9","volume":"190","author":"P Pedicini","year":"2014","unstructured":"Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, Salvatore M, Storto G (2014) Clinical radiobiology of glioblastoma multiforme: Estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol 190:925\u2013932. https:\/\/doi.org\/10.1007\/s00066-014-0638-9","journal-title":"Strahlenther Onkol"},{"key":"5265_CR31","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/cncr.34192","volume":"128","author":"HK Perlow","year":"2022","unstructured":"Perlow HK, Prasad RN, Yang M, Klamer B, Matsui J, Marrazzo L, Detti B, Scorsetti M, Clerici E, Arnett A, Beyer S, Ammirati M, Chakravarti A, Raval RR, Brown PD, Navarria P, Scoccianti S, Grecula JC, Palmer JD (2022) Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials. Cancer 128:2367\u20132374. https:\/\/doi.org\/10.1002\/cncr.34192","journal-title":"Cancer"},{"key":"5265_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11060-021-03925-1","volume":"156","author":"HK Perlow","year":"2022","unstructured":"Perlow HK, Yaney A, Yang M, Klamer B, Matsui J, Raval RR, Blakaj DM, Arnett A, Beyer S, Elder JB, Ammirati M, Lonser R, Hardesty D, Ong S, Giglio P, Pillainayagam C, Goranovich J, Grecula J, Chakravarti A, Gondi V, Brown PD, Palmer JD (2022) Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol 156:399\u2013406. https:\/\/doi.org\/10.1007\/s11060-021-03925-1","journal-title":"J Neurooncol"},{"key":"5265_CR33","unstructured":"ClinicalTrials.gov (2025) A Study of Hypofractionated Radiotherapy in Elderly Patients With Newly Diagnosed Glioblastoma (KROG 21\u2009\u2013\u200911). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05439278. Accessed March 2 2025"},{"key":"5265_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-021-08834-0","volume":"21","author":"Y Arakawa","year":"2021","unstructured":"Arakawa Y, Sasaki K, Mineharu Y, Uto M, Mizowaki T, Mizusawa J, Sekino Y, Ono T, Aoyama H, Satomi K, Ichimura K, Kinoshita M, Ohno M, Ito Y, Nishikawa R, Fukuda H, Nishimura Y, Narita Y (2021) A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC Cancer 21:1105. https:\/\/doi.org\/10.1186\/s12885-021-08834-0","journal-title":"BMC Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05265-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05265-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05265-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:10Z","timestamp":1767702850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05265-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5265"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05265-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Non-applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}